Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current approved options for treating patients with multiple sclerosis.

Syed A Rizvi1, Mark A Agius

  • 1Department of Clinical Neurosciences Brown University, 2 Dudley Street, Suite 555, Providence, Rhode Island 02905, USA. srizvi@lifespan.org

Neurology
|December 30, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Shifting Focus: An Advocacy-Focused Analysis of Omega Beta Iota's Membership and Political Engagement Strategies.

Cureus·2026
Same author

Editorial: Biological therapy for allergic diseases: peculiarities, prospects, and challenges.

Frontiers in allergy·2024
Same author

Local Contrastive Learning for Medical Image Recognition.

AMIA ... Annual Symposium proceedings. AMIA Symposium·2024
Same author

Varicella Zoster Associated Vasculopathy and Retinitis with Natalizumab Use in Multiple Sclerosis.

Rhode Island medical journal (2013)·2024
Same author

Intranasal Xylitol for the Treatment of COVID-19 in the Outpatient Setting: A Pilot Study.

Cureus·2022
Same author

A Randomized Controlled Pilot Trial to Test the Efficacy of Intranasal Chlorpheniramine Maleate With Xylitol for the Treatment of Allergic Rhinitis.

Cureus·2021
Same journal

Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

Neurology·2026
Same journal

Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

Neurology·2026
Same journal

Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

Neurology·2026
Same journal

Spatiotemporal Associations Between Cortical Microinfarcts and Cortical Superficial Siderosis in Cerebral Amyloid Angiopathy.

Neurology·2026
Same journal

Blood-Brain Barrier Disruption Before Interhospital Transfer for Thrombectomy and Clinical Outcome.

Neurology·2026
Same journal

At Death's Door: Cytosolic Dopamine in Patients With Parkinson Disease.

Neurology·2026
See all related articles

Multiple sclerosis (MS) treatments target the inflammatory phase, with immunomodulators for relapsing forms and mitoxantrone for worsening MS. Early intervention with these disease-modifying therapies is crucial for reducing disability.

Area of Science:

  • Neurology
  • Immunology

Background:

  • Multiple sclerosis (MS) is a chronic neurologic disorder affecting 400,000 individuals in the U.S.
  • MS involves distinct inflammatory and neurodegenerative phases.

Purpose of the Study:

  • To review FDA-approved therapies for multiple sclerosis.
  • To discuss disease monitoring methods including disability scales and MRI.
  • To evaluate the clinical efficacy and tolerability of current MS treatments.

Main Methods:

  • Review of FDA-approved therapies for multiple sclerosis.
  • Discussion of disability scales and MRI for disease progression monitoring.
  • Analysis of clinical efficacy and tolerability data for immunomodulators and mitoxantrone.

Main Results:

Related Experiment Videos

  • Immunomodulators (interferon betas, glatiramer acetate) are approved for relapsing forms of MS.
  • Mitoxantrone is approved for worsening relapsing-remitting MS, secondary progressive MS, and progressive-relapsing MS.
  • Current treatments primarily target the inflammatory phase of MS.

Conclusions:

  • Early treatment with disease-modifying agents is recommended to slow MS progression.
  • Timely intervention aims to limit long-term disability in patients with multiple sclerosis.
  • Monitoring disease progression is essential for effective MS management.